SPON2 overexpression in gastric cancer and triple negative breast cancer is reported to be associated with tumorigenicity and aggressive clinical characteristics and poorer outcomes, suggesting it may have a role in malignant progression and metastasis (19, 20). Here, SPON2 is linked to triple-negative breast carcinoma.